An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Myocardial infarction; Peripheral arterial disorders; Peripheral ischaemia; Stroke; Thrombosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms VOYAGER PAD
- Sponsors Bayer; Bayer HealthCare
- 20 Jun 2019 Planned End Date changed from 18 Nov 2019 to 7 Jan 2020.
- 20 Jun 2019 Planned primary completion date changed from 14 Oct 2019 to 22 Nov 2019.
- 02 Apr 2019 Planned End Date changed from 14 Oct 2019 to 18 Nov 2019.